SEC Form 4 · accession 0001237899-15-000016
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur F Ryan
Director
Period of report
Feb 20, 2015
Accepted (ET)
Feb 23, 2015 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 20, 2015 | M | 4,250 | $273.67 | A | 51,750 | D | |
| Common Stock | Feb 20, 2015 | M | 10,000 | $177.82 | A | 61,750 | D | |
| Common Stock | Feb 20, 2015 | M | 10,000 | $57.11 | A | 71,750 | D | |
| Common Stock | Feb 20, 2015 | M | 5,000 | $33.42 | A | 76,750 | D | |
| Common StockF1 | Feb 20, 2015 | S | 2,130 | $421.72 | D | 74,620 | D | |
| Common StockF2 | Feb 20, 2015 | S | 8,196 | $422.52 | D | 66,424 | D | |
| Common StockF3 | Feb 20, 2015 | S | 18,174 | $423.31 | D | 48,250 | D | |
| Common StockF4 | Feb 20, 2015 | S | 750 | $424.58 | D | 47,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $33.42 | Feb 20, 2015 | M | 5,000 | D | — | Jan 3, 2021 | Common Stock | 5,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F5 | $57.11 | Feb 20, 2015 | M | 10,000 | D | — | Jan 3, 2022 | Common Stock | 10,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F5 | $177.82 | Feb 20, 2015 | M | 10,000 | D | — | Jan 2, 2023 | Common Stock | 10,000 | 5,000 | D |
| Non-Qualified Stock Option (right to buy)F5 | $273.67 | Feb 20, 2015 | M | 4,250 | D | — | Jan 2, 2024 | Common Stock | 4,250 | 8,500 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 2,130 shares of Company stock on February 20, 2015 at prices ranging from $421.31 to $421.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 20, 2015 at each separate price.
- F2Represents volume-weighted average price of sales of 8,196 shares of Company stock on February 20, 2015 at prices ranging from $422.00 to $422.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 20, 2015 at each separate price.
- F3Represents volume-weighted average price of sales of 18,174 shares of Company stock on February 20, 2015 at prices ranging from $423.00 to $423.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 20, 2015 at each separate price.
- F4Represents volume-weighted average price of sales of 750 shares of Company stock on February 20, 2015 at prices ranging from $424.29 to $424.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 20, 2015 at each separate price.
- F5The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.